What are the Current and Effective Approaches to Alopecia Areata Treatment in Adults?

Alopecia areata (AA) is a disease characterized by sudden onset, autoimmune-based, inflammatory hair loss. It typically progresses with circular, well-defined areas of hair loss on the scalp. However, it can also affect eyebrows, eyelashes, body hair, and rarely nails. Although the pathogenesis of AA is not fully known, genetic predisposition, environmental triggers, and immune system impairment play important roles. In this article, we discuss current approaches to the treatment of alopecia areata in adults in the light of scientific data.

Clinical Course and Evaluation of AA
The clinical course of AA is quite variable. While mild forms can heal spontaneously, widespread forms can become chronic. Although the disease usually begins in individuals under the age of 30, it is also frequently seen in the adult age group. The SALT score (Severity of Alopecia Tool) is frequently used in clinical evaluation. In addition, the duration of the disease, its prevalence, response to previous treatments, and the presence of accompanying autoimmune diseases should also be taken into account in treatment planning.

Current Options for Alopecia Areata Treatment
1. Topical Treatments
Topical corticosteroids are the first-line options for AA treatment. They are preferred especially in mild and limited cases. Although their clinical efficacy is limited, they are widely used due to their low side effects. Short-term use of high-potency steroids is recommended.

Although topical minoxidil is widely used due to its hair growth-supporting effect, it is not sufficient as monotherapy. Topical contact sensitizers (e.g. DPCP) act by breaking immune tolerance. However, the application process is time-consuming and requires careful monitoring.

2. Injectable Treatments
Intralesional corticosteroids are an effective and safe option, especially in the presence of a limited number of lesions. Triamcinolone acetonide is the most commonly preferred agent. Significant hair growth can be achieved with injections administered at 4-6 week intervals. However, there is a risk of local atrophy as a side effect.

3. Other Topical Approaches
Anthralin: Effective through irritation. It is generally preferred in children.

Tretinoin: It can play a supporting role in combination treatments.

Tazarotene and Tacrolimus: Although its clinical effectiveness is limited, it can be beneficial in some cases.

4. Platelet-Rich Plasma (PRP)
In recent years, PRP applications have become quite popular in the treatment of hair loss. Studies on the effectiveness of PRP in the treatment of AA are promising. The aim is to reactivate hair follicles thanks to the growth factors of PRP. The application is usually done at 2-4 week intervals and in several sessions.

5. Systemic Treatments
a) Oral Corticosteroids
It is generally used in widespread AA cases. There are different protocols such as pulse or low-dose long-term use. However, caution should be exercised due to systemic side effects.

b) Cyclosporine
It can be used in some resistant cases thanks to its immunosuppressive effect. However, side effects such as hypertension and nephrotoxicity may limit its use.

c) Methotrexate and Azathioprine
It can be used to provide systemic immunosuppression in autoimmune hair loss. It is generally preferred in cases that do not respond to other treatments.

6. Biological and Targeted Therapies
One of the groundbreaking developments in the treatment of AA in recent years has been JAK inhibitors. These agents reduce inflammation by blocking cytokine signaling.

a) Tofacitinib and Ruxolitinib
These agents are used especially in severe and widespread AA cases and response rates exceeding 50% have been reported. Significant hair growth can be achieved with 6 months to 1 year of treatment with tofacitinib (5 mg/day) and ruxolitinib (10 mg/day).

b) Baricitinib
It is the first JAK inhibitor to receive FDA approval. It has been reported that significant hair growth was achieved with 36 weeks of treatment at a dose of 4 mg/day. The most common side effects are upper respiratory tract infections.

c) New Generation JAK Inhibitors
More targeted treatment options such as JAK1-2 selective agents are being developed and are currently being tested in clinical trials.

Conclusion
Success in the treatment of alopecia areata depends on the extent, duration and accompanying factors of the disease. While topical agents are the first choice in mild cases, systemic and biological agents should be used in widespread and resistant cases. JAK inhibitors in particular are opening a new era in the treatment of AA and offering promising results in many patients.

However, an individualized approach should be adopted for each patient, and treatment planning should be shaped according to the patient's clinical condition, expectations and quality of life.